Ketek Risk Cannot Be Distinguished From Class, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.